LivingGLP1
Study S002088

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT02690883
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
NONE
Status
COMPLETED
Enrollment
92
Start
2016-04-08
Primary completion
2019-12-13
Lead sponsor
Nanfang Hospital, Southern Medical University
Conditions
Diabetic Nephropathies
Interventions
DRUG:Exenatide; DRUG:Lispro
Results posted
FALSE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24 [from baseline at Week 24]

Linked records (8)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0010237Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, The Cochrane database of systematic reviews
2025Systematic reviewPMID 39963952DOIcites ClinicalTrials.gov:NCT02690883; registry reference DERIVED:39963952
R0011086Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease: a multi-center, randomized, parallel study
Wang X, Research Square
2020Randomized trialDOIcites ClinicalTrials.gov:NCT02690883
R0019255Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway.
Xu WW, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
2014PreclinicalPMID 24556697DOIregistry reference BACKGROUND:24556697
R0012322Effects of glucagon-like peptide-1 receptor agonists on renal function.
Filippatos TD, World journal of diabetes
2013Narrative reviewPMID 24147203DOIregistry reference BACKGROUND:24147203
R0013555The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
Imamura S, The Tohoku journal of experimental medicine
2013Other trialPMID 24064677DOIregistry reference BACKGROUND:24064677
R0027064Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.
Zhang H, Kidney & blood pressure research
2012Randomized trialPMID 22687869DOIregistry reference BACKGROUND:22687869
R0027610Exenatide and rare adverse events.
Ahmad SR, The New England journal of medicine
2008CommentaryPMID 18456920registry reference BACKGROUND:18456920
R0020614Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
Park CW, Journal of the American Society of Nephrology : JASN
2007PreclinicalPMID 17360951DOIregistry reference BACKGROUND:17360951